Loading...
•
Dec 31, 2021
Nuvalent Q4 2021 Earnings Report
Nuvalent reported its fourth quarter and full year 2021 financial results and pipeline progress.
Key Takeaways
Nuvalent reported a net loss of $17.3 million for the fourth quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $288.1 million as of December 31, 2021. The IND application for NVL-655 was cleared by the FDA, and enrollment is ongoing in the ARROS-1 trial of NVL-520.
NVL-655 IND was cleared by the FDA, supporting the planned initiation of the ALKOVE-1 Phase 1/2 clinical trial in Q2 2022.
Enrollment is ongoing in the ARROS-1 trial of NVL-520 for advanced ROS1-positive NSCLC and other solid tumors.
The discovery pipeline continues to advance toward two development candidate nominations in 2022.
Cash, cash equivalents and marketable securities were $288.1 million as of December 31, 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...